1 – 10 of 36
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
Chronotropic Incompetence in Parkinson's Disease : A Possible Marker of Severe Disease Phenotype?
(
- Contribution to journal › Article
-
Mark
Motor Efficacy of Subcutaneous DIZ102, Intravenous DIZ101 or Intestinal Levodopa/Carbidopa Infusion
(
- Contribution to journal › Article
-
Mark
Putaminal T1/T2-weighted ratio is increased in PSP compared to PD and healthy controls, a multi-cohort study
(
- Contribution to journal › Article
-
Mark
PARKIN is not required to sustain OXPHOS function in adult mammalian tissues
(
- Contribution to journal › Article
- 2023
-
Mark
Comorbidities and clinical outcomes in adult- and juvenile-onset Huntington’s disease : a study of linked Swedish National Registries (2002–2019)
(
- Contribution to journal › Article
-
Mark
The Impact of COVID-19 on Parkinson's Disease : A Case-Controlled Registry and Questionnaire Study on Clinical Markers and Patients' Perceptions
(
- Contribution to journal › Article
-
Mark
Age-related differences in the functional topography of the locus coeruleus and their implications for cognitive and affective functions
(
- Contribution to journal › Article
-
Mark
The α-synuclein PET tracer [18F] ACI-12589 distinguishes multiple system atrophy from other neurodegenerative diseases
(
- Contribution to journal › Article
- 2022
-
Mark
Mitochondrial biogenesis, telomere length and cellular senescence in Parkinson’s disease and Lewy body dementia
(
- Contribution to journal › Article
-
Mark
Pharmacokinetics of Intravenously (DIZ101), Subcutaneously (DIZ102), and Intestinally (LCIG) Infused Levodopa in Advanced Parkinson Disease
(
- Contribution to journal › Article